

# The Absorption and Utilization of Vitamin B<sub>12</sub>

By ROBERT F. SCHILLING, M.D.\*

THE HEMOPOIETIC activity of orally administered vitamin B<sub>12</sub> is enhanced by the simultaneous oral administration of intrinsic factor. The mechanism of this enhanced hemopoietic effect has not been proved, but enhanced absorption of the vitamin has been demonstrated beyond reasonable doubt to occur as one action of intrinsic factor. Another possible explanation of the action of intrinsic factor is the formation with vitamin B<sub>12</sub> of a complex which is a more potent hemopoietic agent than vitamin B<sub>12</sub> alone. Intrinsic factor might also retard bacterial utilization of intestinal vitamin B<sub>12</sub> and thus allow the host to absorb more of the vitamin.

When it was established that vitamin B<sub>12</sub> was an extrinsic (food) factor as well as an anti-pernicious anemia factor, a logical function to assign to intrinsic factor was the promotion of intestinal absorption of the vitamin.<sup>1</sup> Heinle, Welch, Scharf, Meacham and Prusoff<sup>2</sup> demonstrated that intrinsic factor decreased fecal radioactivity in patients with pernicious anemia given radioactive vitamin B<sub>12</sub> (B<sub>12</sub>Co<sup>60</sup>) by mouth. A reasonable conclusion was that intrinsic factor enhanced the absorption of the vitamin. Table I is a compilation of data from the literature in which the fecal radioactivity test was used to study pernicious anemia patients for their ability to absorb vitamin B<sub>12</sub> from the gastrointestinal tract.

The liver has long been known to be a good source of the anti-pernicious anemia factor. The vitamin B<sub>12</sub> normally in the liver must have been absorbed from the intestine. Glass

and co-workers<sup>3</sup> demonstrated that the liver of normal persons who ingest radioactive vitamin B<sub>12</sub> will contain radioactivity detectable by external scintillation counting, but the patient with pernicious anemia does not demonstrate such radioactivity unless intrinsic factor is given with the ingested radioactive vitamin. These workers have clearly demonstrated an inverse relationship between the oral dose of vitamin B<sub>12</sub> and the percentage of the dose deposited in the liver, i.e. absorbed.<sup>4</sup> Swensid and her colleagues<sup>5</sup> have demonstrated a similar limit of absorption of vitamin B<sub>12</sub> as estimated by the fecal radioactivity technic.

TABLE I

Summary of Fecal Radioactivity Excretion Data in Pernicious Anemia

| No. patients | Observations | Intrinsic factor | Per cent radioactivity excreted |
|--------------|--------------|------------------|---------------------------------|
| 34           | 50           | —                | 72-100                          |
| 23*          | 27           | added            | 25-66                           |

\* Of the 34 patients above.

Normal subjects who take 1 or 2  $\mu$ g. of radioactive vitamin B<sub>12</sub> by mouth will excrete none of the radioactivity in the urine in the following 24 hours unless a large (1000  $\mu$ g.) "flushing" dose of nonradioactive vitamin B<sub>12</sub> is injected about the time of taking the oral labeled vitamin.<sup>6</sup> Using this "in vivo carrier" technique, 9 normal subjects excreted 7-21 per cent of the orally administered radioactivity in the 24-hour urine, whereas 23 patients with pernicious anemia excreted from 0-2.3 per cent of the radioactivity in the 24-hour urine (Table II).

It is to be noted that 26 subjects with histamine-fast achlorhydria but no other history or signs of pernicious anemia excreted from 3.2-29.6 per cent of the radioactivity in the urine. The radioactivity appearing in the

From the Department of Medicine, University of Wisconsin Medical School, Madison, Wis.

\* Assistant Professor of Medicine, University of Wisconsin Medical School.

The author's studies were supported by grants from the National Institutes of Health (A-69) and Armour Laboratories.

TABLE II  
Urinary Radioactivity after Oral Vitamin B<sub>12</sub>CO<sup>60</sup>

| No. patients | Status            | Gastric acid | Added intrinsic factor | Per cent |         |         |
|--------------|-------------------|--------------|------------------------|----------|---------|---------|
|              |                   |              |                        | Minimum  | Maximum | Average |
| 9            | control           | present      | —                      | 7.0      | 21.0    | 14.7    |
| 26           | no P.A.*          | achlorhydria | —                      | 3.2      | 29.6    | 13.0    |
| 23           | P.A.              | —            | —                      | 0        | 2.3     | 0.6     |
| 19           | P.A.              | —            | +                      | 3.4      | 15.0    | 9.5     |
| 8            | Total gastrectomy | —            | —                      | 0        | 1.0     | 0.2     |

\* P.A. = pernicious anemia.

The figures represent the per cent of orally administered radioactivity which was excreted in the urine collected for 24 hours after ingestion of the radioactive vitamin.

urine in this test has been shown by MacLean and Bloch<sup>7</sup> to have a chromatographic mobility identical with vitamin B<sub>12</sub>. They also report that 3 normal individuals excreted 20–29 per cent of the orally administered radioactivity in the urine within the first 24 hours, corresponding to 34–39 per cent of the absorbed dose.

Figure 1 is a scattergraph of urine volume versus urine radioactivity, and it is apparent




Fig. 1 Scattergraph of urine radioactivity versus urine volume in 27 subjects with histamine-fast achlorhydria but no other evidence of pernicious anemia. Details of technique in text.

that the two functions are not directly dependent.

Chow<sup>8</sup> has reported data suggesting that elderly subjects might absorb vitamin B<sub>12</sub> less efficiently than young persons. Figure 2

is a scattergraph plotting age of subject against urine radioactivity after oral radioactive vitamin B<sub>12</sub>. These data offer no support for the theory that older persons absorb vitamin B<sub>12</sub> less efficiently than do younger subjects. The data in Figure 2 are evidence that most achlorhydric subjects without other signs of pernicious anemia function as do the control subjects in this test of vitamin B<sub>12</sub> absorption and excretion.




Fig. 2 Scattergraph of urine radioactivity versus age of patient. See text for technique.

As estimated by the urinary excretion of radioactivity, the absorption of vitamin B<sub>12</sub> by a patient with pernicious anemia was not increased when the intestinal bacterial population was reduced by oxytetracycline therapy.<sup>6</sup> Thus, as in Ungley's earlier study<sup>9</sup>

using hemopoiesis as an index of vitamin absorption, no evidence was found to suggest that intestinal bacteria were preventing vitamin B<sub>12</sub> absorption. The observed hemopoietic effects of antibiotics in some megaloblastic anemias<sup>10,11</sup> might be due to increased bacterial production of folic acid or citrovorum factor. As would be anticipated from the earlier work of Castle,<sup>12</sup> Paulson, Conley, and Gladsden,<sup>13</sup> McDonald, Inglefinger, and Belding,<sup>14</sup> studies with radioactive vitamin B<sub>12</sub> have demonstrated that totally gastrectomized patients are quantitatively similar to patients with pernicious anemia in their inability to absorb vitamin B<sub>12</sub><sup>15,16</sup> (Table II). Two of the patients in our series had had end-to-end esophago-duodenostomies, and their vitamin B<sub>12</sub> absorption was as low as in those patients having an esophago-jejunosomy with a blind loop of duodenum. The data from observations on totally gastrectomized persons also indicate that the stomach is not necessary for vitamin B<sub>12</sub> absorption if intrinsic factor is supplied. The small intestine may be considered the site of absorption of vitamin B<sub>12</sub>.

The vitamin B<sub>12</sub> content of the feces from a patient with pernicious anemia in relapse is more than adequate to treat him by injection.<sup>17</sup> Patients with pernicious anemia in relapse have been treated by intramuscular injections of vitamin B<sub>12</sub> extracted from their own feces.<sup>18</sup> If intrinsic factor is given 12 hours before the oral vitamin B<sub>12</sub>, the hemopoietic activity of the vitamin will not be increased.<sup>1</sup> From this one might conclude that the intrinsic factor is inactivated during this period, or, possibly, when the intrinsic factor has reached the colon, it can no longer effect the absorption of vitamin B<sub>12</sub>. Evidence for the latter postulate is the observation by Best and colleagues,<sup>19</sup> who found that an enema of radioactive vitamin B<sub>12</sub> and intrinsic factor did not lead to urinary excretion of radioactivity after a "flushing" injection of non-radioactive vitamin B<sub>12</sub>.

The poor absorption of vitamin B<sub>12</sub> observed frequently in sprue is not corrected by adding intrinsic factor.<sup>3</sup>

If massive oral doses of vitamin B<sub>12</sub> (1000-5000  $\mu$ g./day) are given to patients with per-

nicious anemia in relapse, excellent hemopoietic responses will be observed in the absence of added intrinsic factor.<sup>9</sup> Nasal instillation and aerosol inhalation of vitamin B<sub>12</sub> have been reported as effective modes of therapy for pernicious anemia.<sup>20,21</sup> Intramuscular injections of vitamin B<sub>12</sub> at three-to four-week intervals in amounts equal to 1  $\mu$ g./day have been found to be satisfactory for maintenance therapy.<sup>22</sup>

Latner and his colleagues<sup>23</sup> have reported the "isolation of the intrinsic factor." At the oral dose level of 1 mg., their material decreased the fecal radioactivity in patients with pernicious anemia given radioactive vitamin B<sub>12</sub>. By electrophoretic and ultracentrifugal study this preparation was considered to be pure. In unpublished observations by the author a hog mucosal concentrate\* was found to be active at 1 and 2 mg. levels in the urinary radioactivity assay for intrinsic factor.

Several chemical forms of vitamin B<sub>12</sub> in addition to cyano-cobalamin are known.<sup>24,25</sup> Hydroxo-cobalamin<sup>25,26</sup> and nitro-cobalamin<sup>25</sup> (vitamin B<sub>12c</sub>) possess anti-pernicious anemia activity when injected. Hydroxo-cobalamin will also serve as an extrinsic factor;<sup>26</sup> hence any postulated chemical bond between extrinsic and intrinsic factors cannot be dependent upon the specific cyanocobalamin configuration. Pseudo-vitamin B<sub>12</sub> contains an adenine moiety instead of the 5,6-dimethyl benzimidazole of the usual cobalamins, and it is reported to lack anti-pernicious anemia activity.<sup>27</sup>

Vitamin B<sub>12</sub> which is absorbed has a slow turnover rate. The prolonged remissions<sup>28</sup> which sometimes persist in patients with pernicious anemia after therapy with B<sub>12</sub> is discontinued suggest this. Direct observations of hepatic radioactivity after therapy with radioactive vitamin B<sub>12</sub> show that much of the activity remains in the liver for more than one year. That excessive metabolic activity may increase the need for vitamin B<sub>12</sub> is suggested by the fact that there are in the literature at least 75 instances of the co-

\* Supplied to the author by W. F. White of Armour Laboratories.

existence of hyperthyroidism and pernicious anemia.<sup>29</sup> The author feels that this figure is higher than would be anticipated from chance alone: statistical proof, however is not available. The hypermetabolic rat has an increased vitamin B<sub>12</sub> requirement.<sup>30</sup>

The classical human example of vitamin B<sub>12</sub> deficiency is that caused by an unexplained lack of intrinsic factor activity, pernicious anemia. The parenteral injection of vitamin B<sub>12</sub> will completely correct the hematologic defects of this disease, and the neurologic defects will be halted or reversed. The sore tongue will disappear. Lajtha<sup>31</sup> and Thompson<sup>32</sup> have reported independently that vitamin B<sub>12</sub> added *in vitro* to cultures of marrows from pernicious anemia patients did not cause a maturation of the megaloblasts. Folic acid, however, did cause such a maturation *in vitro*. When vitamin B<sub>12</sub> was added with intrinsic factor, maturation occurred. Horrigan, Jarrold, and Vilter<sup>33</sup> demonstrated that local *in vivo* instillation of vitamin B<sub>12</sub> into one iliac marrow caused local maturation of that marrow in 24 hours, but not of the marrow in the opposite ilium of the patient with pernicious anemia. Wallerstein and colleagues<sup>34</sup> found no consistent evidence that intravenous B<sub>12</sub> and gastric juice was a more effective hemopoietic combination than intravenous vitamin B<sub>12</sub> alone.

The fact that the cells from the vaginal and gastric mucosa in pernicious anemia in relapse are macrocytic and often multinucleated<sup>35</sup> is evidence that vitamin B<sub>12</sub> is required for normal development of cells from several systems in addition to the hemopoietic and neurologic.

#### SUMMARY

The absorption of vitamin B<sub>12</sub> in the small intestine from the dietary intake requires an adequate supply of intrinsic factor. In man, the only apparent gastrointestinal source of intrinsic factor is the gastric mucosa. Less than 1 µg./day is the normal requirement of absorbed vitamin B<sub>12</sub>. The total daily dietary requirement is not known. There is evidence that the biologic rate of decay of this vitamin is relatively slow.

#### REFERENCES

1. BERK, L., CASTLE, W. B., WELCH, A. D., HEINLE, R. W., ANKER, R., and EPSTEIN, M.: Observations on the etiologic relationship of achylia gastrica to pernicious anemia. X. Activity of vitamin B<sub>12</sub> as food (extrinsic) factor. *New England J. Med.* 239: 911, 1948.
2. HEINLE, R. W., WELCH, A. D., SCHARF, V., MEACHAM, G. C., and PRUSOFF, W. H.: Studies of excretion (and absorption) of Co<sup>60</sup>-labeled vitamin B<sub>12</sub> in pernicious anemia. *Tr. A. Am. Physicians* 65: 214, 1952.
3. GLASS, G. B. J., BOYD, L. J., GELLIN, G. A., and STEPHANSON, L.: Uptake of radioactive vitamin B<sub>12</sub> by the liver in humans: Test for measurement of intestinal absorption of vitamin B<sub>12</sub> and intrinsic factor activity. *Arch. Biochem. & Biophysics* 51: 251, 1954.
4. GLASS, G. B. J., BOYD, L. J., STEPHANSON, L.: Intestinal absorption of vitamin B<sub>12</sub> in humans as studied by isotope technic. *Proc. Soc. Exper. Biol. & Med.* 86: 522, 1954.
5. SWENDEID, M. E., GASSTER, M. and HALSTED, J. A.: Limits of absorption of orally administered vitamin B<sub>12</sub>: Effect of intrinsic factor sources. *Proc. Soc. Exper. Biol. & Med.* 86: 834, 1954.
6. SCHILLING, R. F.: Intrinsic factor studies II. The effect of gastric juice on the urinary excretion of radioactivity after the oral administration of radioactive vitamin B<sub>12</sub>. *J. Lab. & Clin. Med.* 42: 860, 1953.
7. MACLEAN, L. D., and BLOCH, H. S.: Gastrointestinal absorption and urinary excretion of vitamin B<sub>12</sub>Co<sup>60</sup>. *Proc. Soc. Exper. Biol. & Med.* 87: 171, 1954.
8. CHOW, B. F.: Vitamin B<sub>12</sub> and aging. *Fed. Proc.* 13: 453, 1954.
9. UNGLEY, C. C.: Absorption of vitamin B<sub>12</sub> in pernicious anemia. *Brit. M. J.* 2: 905, 1950.
10. LICHTMAN, H., GINSBERG, V., and WATSON, J.: Therapeutic effect of aureomycin in pernicious anemia. *Proc. Soc. Exper. Biol. & Med.* 74: 884, 1950.
11. FOY, H., and KONDI, A.: Treatment of megaloblastic anemias. Relation of penicillin to vitamin B<sub>12</sub>. *Lancet* 2: 1280, 1953.
12. CASTLE, W. B., TOWNSEND, W. C., and HEATH, C. W.: Observations on the etiologic relationship of achylia gastrica to pernicious anemia. III. The nature of the reaction between normal human gastric juice and beef muscle leading to clinical improvement and increased blood formation similar to the effect of liver feeding. *Am. J. M. Sc.* 180: 305, 1930.
13. PAULSON, M., CONLEY, C. L., and GLADSDEN, E. S.: I. Absence of intrinsic factor from intestinal juice of patients following total gastrectomy. *Am. J. M. Sc.* 219: 310, 1950.
14. McDONALD, R. M., INGLEFINGER, F. J., and BELD-





- ING, H. W.: Late effects of total gastrectomy in man. *New England J. Med.* 237: 887, 1947.
15. HALSTED, J. A., GASSTER, M., and DRENICK, E. J.: Absorption of radioactive vitamin B<sub>12</sub> after total gastrectomy. Relation to macrocytic anemia and to the site of origin of Castle's intrinsic factor. *New England J. Med.* 251: 161, 1954.
  16. LEY, A. B., and SHARPE, L. E.: The absorption of vitamin B<sub>12</sub> after total gastrectomy. *Clin. Res. Proc.* 2: 31, 1954.
  17. BETHELL, F. H., MEYERS, M. C., and NELIGH, R. B.: Vitamin B<sub>12</sub> in pernicious anemia and pueblo macrocytic anemia. *J. Lab. & Clin. Med.* 33: 1477, 1948.
  18. CALLENDER, T. E., and SPRAY, G. H.: Preparation of hemopoietically active extracts from feces. *Lancet* 1: 1391, 1951.
  19. BEST, W. R., WHITE, W. F., LOUIS, J., and LIMARZI, L. R.: Experiences with the Schilling test using Co<sup>60</sup>-labeled vitamin B<sub>12</sub> in pernicious anemia, sprue, and other conditions. *J. Lab. & Clin. Med.* 44: 767, 1954.
  20. MONTO, R. W., REBUCK, J. W., and HOWELL, J. T.: The single intranasal application of vitamin B<sub>12</sub> crystals in pernicious anemia. *Proc. Central Soc. Clin. Research* 27: 86, 1954.
  21. MONTO, R. W., REBUCK, J. W., and BRENNAN, M. J.: Crystalline B<sub>12</sub> inhalation therapy in pernicious anemia. *Am. J. M. Sc.* 225: 113, 1953.
  22. MEACHAM, G. C., and HEINLE, R. W.: Maintenance therapy of pernicious anemia with vitamin B<sub>12</sub>. *J. Lab. & Clin. Med.* 41: 65, 1953.
  23. LATNER, A. L., MERRILLS, R. J., and RAINE, L.C.D.P.: Isolation of Castle's intrinsic factor. *Lancet* 1: 497, 1954.
  24. KACZKA, E. A., WOLF, D. E., KUEHL, F. A., and FOLKERS, K.: Vitamin B<sub>12</sub>: Reactions of cyanocobalamin and related compounds. *Science* 112: 354, 1950.
  25. UNGLEY, C. C.: Vitamin B<sub>12</sub> and other dietary factors in megaloblastic anemias and in subacute combined degeneration of the cord. *Proc. Roy. Soc. Med.* 43: 535, 1950.
  26. SCHILLING, R. F., HARRIS, J. W., and CASTLE, W. B.: Observations on the etiologic relationship of achylia gastrica to pernicious anemia. XIII. Hematopoietic activity of vitamin B<sub>12a</sub> (vitamin B<sub>12b</sub>). *Blood* 6: 228, 1951.
  27. PFIFFNER, J. J., DION, H. W., and CALKINS, D. G.: Further characterization of pseudovitamin B<sub>12</sub> pigments. *Fed. Proc.* 11: 269, 1952.
  28. STRAUSS, M. B., and POHLE, F. J.: The duration of remission in pernicious anemia with liver therapy. The efficacy of massive doses administered at one time. *J. A. M. A.* 114: 1318, 1940.
  29. WINTROBE, M. M.: *Clinical Hematology* (third edition), Lea and Febiger, Philadelphia, 1951.
  30. LEWIS, U. J., REGISTER, U. D., THOMPSON, H. T., and ELVEHJEM, C. A.: Distribution of vitamin B<sub>12</sub> in natural materials. *Proc. Soc. Exper. Biol. & Med.* 72: 479, 1949.
  31. LAJTHA, L. G.: Inhibitory factor in pernicious anemia serum. *Clin. Sc.* 9: 287, 1950.
  32. THOMPSON, R. B.: Observations on effects of vitamin B<sub>12</sub>, liver extracts, folic acid and thymine on maturation of megaloblasts in culture. *Blood* 7: 522, 1952.
  33. HERRIGAN, D., JARROLD, T., and VILTER, R. W.: Direct action of vitamin B<sub>12</sub> upon human bone marrow. The effect of instillations of vitamin B<sub>12</sub> and folic acid into the bone marrow as studied by nucleic acid staining techniques. *J. Clin. Investigation* 30: 31, 1951.
  34. WALLERSTEIN, R. O., HARRIS, J. W., SCHILLING, R. F., and CASTLE, W. B.: Observations on the etiologic relationship of achylia gastrica to pernicious anemia. XV. Hematopoietic effects of simultaneous intravenous or serial oral administration of intrinsic factor and vitamin B<sub>12</sub>. *J. Lab. & Clin. Med.* 41: 363, 1953.
  35. GRAHAM, R. M., and RHEAULT, M. H.: Characteristic cellular changes in epithelial cells in pernicious anemia. *J. Lab. & Clin. Med.* 43: 235, 1954.

## DISCUSSION

DR. J. R. KREVANS (Baltimore, Md.): I'd like to make just a few very brief comments about Dr. Schilling's excellent paper, and ask some questions.

We got very much the same results that Dr. Schilling did with respect to age, using the technique of feeding a patient a certain amount of labeled vitamin B<sub>12</sub> and recovering radioactivity in the feces. We feel that this adds strength to the argument. At least, by these two techniques, age does not seem to be an

important factor in the percentage of B<sub>12</sub> absorbed, and I think our method of study helps to strengthen that argument because it bypasses the question of whether or not the elderly individual's kidneys are working as well as the young adult's.

Second, we were able to confirm the observations about the inability of terramycin to improve the absorption of vitamin B<sub>12</sub> in patients with pernicious anemia.

We had an opportunity to study an indivi-

dual who had a vitamin B<sub>12</sub> deficiency on another basis, multiple small intestinal diverticulae, and who had neurologic changes. Now, this individual's B<sub>12</sub> absorption was very definitely improved by the prior administration of terramycin, suggesting that at least in this situation bacterial competition played an important role.

This observation is confirmed by a very interesting case report by Scandinavian workers, who reported a patient with multiple intestinal strictures and fistula who had pernicious anemia, and who had a clinical and hematological response to the administration of terramycin rather than vitamin B<sub>12</sub>. I think it is worth pointing out that not all patients with sprue have an absorption defect for vitamin B<sub>12</sub>, and I think both Dr. Glass and our group have found some individuals with a full-blown picture of sprue who are able to absorb vitamin B<sub>12</sub> perfectly normally.

Finally, we have been able to follow some 50 patients now, with pernicious anemia, who have been treated with orally administered vitamin B<sub>12</sub>. Ten of these patients have been started and maintained on orally administered B<sub>12</sub>, and some 20 patients have been started on oral B<sub>12</sub> but not maintained on this therapy. Others have been maintained on oral B<sub>12</sub>, although they had been started on liver extract or parenteral vitamin B<sub>12</sub>. The longest any of these patients has been maintained on oral B<sub>12</sub> has been since the winter of 1950. The patients received initially five milligrams of vitamin B<sub>12</sub> orally, without any gastric juice or intrinsic factor, and are maintained on one milligram per week. To date, we have had no clinical or hematological relapses on this schedule.

I would like to ask Dr. Mueller this question: Do those patients with pernicious anemia who were maintained on folic acid for long periods of time, and who eventually relapsed, show a picture of hypoplasia in the bone marrow, and no megaloblastic changes? I'd like to hear this discussed further. It is so convenient to think of the megaloblastic picture as part of the same general B<sub>12</sub> deficiency state that causes immature cells to be found in the gastric mucosa, and I wonder why

these individuals do not have megaloblastic marrows when all their B<sub>12</sub> has been consumed?

DR. J. F. MUELLER (Cincinnati, Ohio): The observation has been repeatedly noted that a hypocellular nonmegaloblastic bone marrow is present in patients who are treated for months or years with folic acid. We interpret this finding as showing a severe B<sub>12</sub> deficiency, certainly with no folic acid deficiency. It fits in well with the published reports of experiments with swine. In these animals pure dietary B<sub>12</sub> deficiency did not produce megaloblastic changes in the bone marrow, whereas folic acid deficiency did.

DR. D. L. HERRIGAN (Cincinnati, Ohio): Certainly Dr. Will's data on the different ratios in pernicious anemia marrows are very interesting. I wonder how much of that might be due to simple immaturity of the marrow. And I wonder if he has any data on an iron deficiency marrow or one that is hyperplastic due to acute hemolytic anemia, to show that the immaturity itself is not responsible for these changes.

DR. J. J. WILL (Cincinnati, Ohio): Yes, we feel this is not evidence of mere immaturity, but is a specific change that took place in the megaloblastic type cells.

DR. B. CONNOR JOHNSON (Urbana, Ill.): As many of you know, we have been working with vitamin B<sub>12</sub> deficiency, using the baby pig as experimental animal, for the past five years. B<sub>12</sub>-deficient baby pigs do not show a megaloblastic anemia, even though they do die of the deficiency, usually within two to four weeks.

A severe choline deficiency can also readily be produced in the baby pig. As in the rat, this choline requirement can be replaced by dietary methionine. In order to study the interrelationship between this choline requirement and vitamin B<sub>12</sub>, a series of *in vivo* and *in vitro* experiments have been carried out. The first group of experiments were designed to find out whether vitamin B<sub>12</sub> is involved in direct transmethylation reactions. *In vivo*

it was found that baby pigs on a B<sub>12</sub>-deficient, choline-free diet, containing sufficient methionine to provide both sulfur amino acid and methyl requirements of the animal, were able to transmethylate from this methionine to make choline for prevention of fatty livers just as well as were B<sub>12</sub>-adequate animals. There was no evidence of choline deficiency even in animals dying of B<sub>12</sub> deficiency in this experiment. This fact, that B<sub>12</sub> is not involved in direct transmethylation from methionine to form choline, was confirmed in *in vitro* studies with liver homogenates of B<sub>12</sub>-deficient as compared to normal pigs and chickens. Differences in direct transmethylating ability were found in rats, on the other hand, and may be related to apoenzyme formation, or to some other effect, I am not sure. I would be interested in hearing Dr. Williams' comments on this.

Since we didn't find vitamin B<sub>12</sub> involved in transmethylation, we of course examined methyl synthesis, following the line of approach used by Dr. Stekol and Dr. Arnstein. In *in vivo* experiments we fed baby pigs glycine as a possible methyl precursor. On choline-free diets containing only enough methionine to satisfy the animals' needs for sulfur amino acids, the B<sub>12</sub>-deficient pigs on these diets all showed a severe choline deficiency; however, with vitamin B<sub>12</sub> added,

there were no fatty livers and no evidence of choline deficiency, indicating, therefore, by a straight nutrition experiment, that B<sub>12</sub> is required for methyl synthesis from, in this case, glycine; that is, in the presence of vitamin B<sub>12</sub> glycine completely replaced choline in the diet. This was substantiated by tracer experiments in these pigs in which the C<sup>14</sup> of  $\alpha$ -labeled glycine was found to be incorporated into the methyl groups of choline in the presence of B<sub>12</sub>, while only to about a tenth as much in the absence of vitamin B<sub>12</sub>.

DR. J. N. WILLIAMS (Madison, Wis.): These experiments actually seem to point up exactly what I was trying to bring out this morning: that there are many reactions in some way associated with folic acid and vitamin B<sub>12</sub>, but the *exact* steps at which the vitamins are involved cannot be stated with any certainty. An easy explanation is that in the case of the pig one is dealing with a different type of enzyme than in the rat. However, I wouldn't like to make that statement without equivocation. I am able to think of an example of an enzyme that is different in its mechanics of action in one animal as compared to another. That is xanthine oxidase in the rat as compared to xanthine dehydrogenase of the chick. That is one possibility, but beyond that I have no other explanation.

